Clinical Trial

Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this first-in-human (FiH) study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of CKD-512 given alone and in combination with pembrolizumab in subjects with advanced or metastatic solid tumors who have failed all standard available therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-02.
Status change: Not Yet Recruiting → Recruiting 2026-01-29
Trial Details
NCT Number NCT07215637
Lead Sponsor Chong Kun Dang Pharmaceutical
Conditions Advanced Solid Tumors, Metastatic Solid Tumors
Enrollment 60 participants
Start Date 2025-10-16
Primary Completion 2027-03 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-02-02